# Pain Treatment * **Definition:** Pain Treatment refers to the various medical and therapeutic interventions aimed at alleviating or managing pain experienced by patients, which may include medications, physical therapy, psychological support, and alternative therapies. * **Taxonomy:** Healthcare Topics / Pain Treatment ## News * Selected news on the topic of **Pain Treatment**, for healthcare technology leaders * 3.2K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/23/2025 | [**Ethical Governance in Generative AI for Insurance - by OCTAVE - John Keells Group**](https://medium.com/@octave-jkh/ethical-governance-in-generative-ai-for-insurance-e1d12a97c037) | [[Medium]] | | 5/8/2025 | [**Judi Health™ Earns Best Healthcare InsurTech Solution in the 9th Annual MedTech ...**](https://www.prnewswire.com/news-releases/judi-health-earns-best-healthcare-insurtech-solution-in-the-9th-annual-medtech-breakthrough-awards-program-302449699.html) | [[PR Newswire]] | | 4/28/2025 | [**AI In Healthcare Market Size to Reach $187.7 Billion by 2030 at CAGR 38.5**](https://finance.yahoo.com/news/ai-healthcare-market-size-reach-140500267.html) | [[Yahoo Finance]] | | 4/10/2025 | [**UQ's new research center aims to improve lives of people living with pain**](https://www.news-medical.net/news/20250410/UQs-new-research-center-aims-to-improve-lives-of-people-living-with-pain.aspx) | [[News Medical Net]] | | 3/25/2025 | [**SAFE Project and Alternative Pain Treatment Directory Announce Strategic Partnership to Prevent Addiction and Overdose Deaths**](https://www.prweb.com/releases/safe-project-and-alternative-pain-treatment-directory-announce-strategic-partnership-to-prevent-addiction-and-overdose-deaths-302407649.html) | [[PRWeb]] | | 3/25/2025 | [**NorCal Pain Treatment Center Launches PatchRx to Strengthen Adherence and Outcomes**](https://www.prnewswire.com/news-releases/norcal-pain-treatment-center-launches-patchrx-to-strengthen-adherence-and-outcomes-302410332.html) | [[PR Newswire]] | | 3/16/2025 | [**Latigo secures $150m for non-opioid pain treatment development**](https://finance.yahoo.com/news/latigo-secures-150m-non-opioid-145416599.html) | [[Yahoo Finance]] | | 3/11/2025 | [**Where Will Vertex Pharmaceuticals Be in 10 Years?**](https://www.aol.com/where-vertex-pharmaceuticals-10-years-082500973.html) | [[AOL]] | | 3/4/2025 | [**Nervonik Raises $13 Million in Series A Financing to Advance Next-Generation Peripheral ...**](https://www.prnewswire.com/news-releases/nervonik-raises-13-million-in-series-a-financing-to-advance-next-generation-peripheral-nerve-stimulation-for-chronic-pain-relief-302390811.html) | [[PR Newswire]] | | 2/11/2025 | [**OCT Holdings Announces Rebrand to Octavian Therapeutics, Appointment of New Chair and Fundraising Launch**](https://www.prnewswire.com/news-releases/oct-holdings-announces-rebrand-to-octavian-therapeutics-appointment-of-new-chair-and-fundraising-launch-302373846.html) | [[PR Newswire]] | | 2/6/2025 | [**CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain ...**](https://www.morningstar.com/news/accesswire/980797msn/cenexel-celebrates-fda-approval-of-journavxtm-a-groundbreaking-non-opioid-pain-treatment) | [[Morningstar]] | | 2/6/2025 | [**Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio**](https://finance.yahoo.com/news/globus-medical-acquire-nevro-250-184918916.html) | [[Yahoo Finance]] | | 2/4/2025 | [**Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment**](https://www.morningstar.com/news/accesswire/979709msn/ensysce-biosciences-reports-continued-positive-progress-in-groundbreaking-trial-on-pf614-mpar-comments-on-current-landscape-for-pain-treatment) | [[Morningstar]] | | 1/29/2025 | [**Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 ...**](https://finance.yahoo.com/news/adolore-biotherapeutics-present-ca8-neuromodulating-130000760.html) | [[Yahoo Finance]] | | 1/8/2025 | [**Global Pain Treatment Market to Reach $144.2 Billion by 2029 - Yahoo Finance**](https://finance.yahoo.com/news/global-pain-treatment-market-reach-190400315.html) | [[Yahoo Finance]] | | 1/3/2025 | [**Conventional and Alternative Pain Treatment Market Research 2024-2029, Profiles of Market Leaders - Medtronic, Abbott, GSK, Pfizer Inc., and Johnson & Johnson - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20250103965508/en/Conventional-and-Alternative-Pain-Treatment-Market-Research-2024-2029-Profiles-of-Market-Leaders---Medtronic-Abbott-GSK-Pfizer-Inc.-and-Johnson-Johnson---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/31/2024 | [**Conventional and Alternative Pain Treatment Market Research 2024-2029 - Yahoo Finance**](https://finance.yahoo.com/news/conventional-alternative-pain-treatment-market-102600219.html) | [[Yahoo Finance]] | | 12/18/2024 | [**Founder of travel tech startup Nuitee raised $48 million for its next phase - Fortune**](https://fortune.com/2024/12/18/founder-of-travel-tech-startup-nuitee-raised-48-million-for-its-next-phase-thats-when-we-start-pissing-people-off/) | [[Fortune]] | | 11/14/2024 | [**CureLab Oncology Seeks to Revolutionize Chronic Pain Management with Novel p62 ...**](https://www.prnewswire.com/news-releases/curelab-oncology-seeks-to-revolutionize-chronic-pain-management-with-novel-p62-based-therapy-302305218.html) | [[PR Newswire]] | | 11/11/2024 | [**How alternative therapies could be the key to ending the pain care crisis [PODCAST]**](https://kevinmd.com/2024/11/how-alternative-therapies-could-be-the-key-to-ending-the-pain-care-crisis-podcast.html) | [[KevinMD]] | | 11/4/2024 | [**CMS bumps hospital outpatient rates 2.9n 2025: 10 notes**](https://www.beckershospitalreview.com/finance/cms-bumps-hospital-outpatient-rates-2-9-in-2025-10-notes.html) | [[Beckers Hospital Review]] | | 10/10/2024 | [**Vertex, nearing finish line for non-opioid drug, delves into current difficulties in pain treatment**](https://www.fiercepharma.com/marketing/vertex-nearing-finish-line-non-opioid-drug-delves-current-difficulties-pain-treatment) | [[FiercePharma]] | | 7/30/2024 | [**Hinge Health**](https://medcitynews.com/tag/hinge-health/) | [[MedCity News]] | | 11/17/2020 | [**Patients pay thousands for a back pain treatment with little scientific support**](https://www.yahoo.com/news/patients-pay-thousands-back-pain-120536197.html) | [[Yahoo]] | | 7/12/2007 | [**Mass. doctor faces drug charges over pain treatment**](https://www.fiercehealthcare.com/healthcare/mass-doctor-faces-drug-charges-over-pain-treatment) | [[FierceHealthcare]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Channel Therapeutics**: A company pursuing non-opioid pain treatments, focusing on NaV1.7 inhibitors for various pain conditions. - **Profound Medical Corp.**: Specializes in incision-free therapies for pain treatment, including the TULSA-PRO® system for prostate conditions. - **Channel Therapeutics Corporation**: A company specializing in non-opioid pain treatments, particularly NaV1.7 inhibitors for various pain conditions. - **Adolore Biotherapeutics, Inc.**: Focused on non-opioid analgesic treatments for chronic pain, developing therapies based on carbonic anhydrase-like analgesic peptides. - **Nevro Corp.**: A company focused on innovative solutions for chronic pain treatment, particularly known for its proprietary 10 kHz Therapy. - **TheraLight, LLC**: Specializes in whole-body LED photobiomodulation technology for pain relief and rehabilitation. - **Medasense**: A pain management technology company known for its nociception monitoring device that utilizes AI for real-time pain assessment. - **National Institutes of Health (NIH)**: U.S. government agency that funds research initiatives aimed at understanding and improving pain treatment, including studies on healthcare provider biases. - **Latigo Biotherapeutics**: Developing Nav1.8 inhibitors as non-opioid pain treatments, recently raised $150 million in funding. - **Vertex Pharmaceuticals**: Developing suzetrigine, a non-opioid pain signal inhibitor, aimed at addressing acute pain management. - **Bioventus Inc.**: A company focused on providing clinically proven and cost-effective healing products, including pain treatments. - **CureLab Oncology**: A biopharmaceutical company developing Elenagen, a novel chronic pain treatment targeting chronic inflammation. - **NextGen Healthcare**: Provider of electronic health record (EHR) and practice management solutions, enhancing operations for pain management clinics. - **Allay Therapeutics**: A company developing ATX101, a novel formulation of bupivacaine for post-surgical pain management, which has received Breakthrough Therapy designation from the FDA. - **Washington University School of Medicine**: This institution is conducting research on chronic post-surgical pain, receiving NIH funding to develop personalized risk-assessment and pain management tools. - **Brixton Biosciences**: A clinical-stage life sciences company developing Neural Ice, a non-opioid injectable solution for long-lasting pain relief, supported by a grant from the NIH HEAL Initiative. - **Innocan Pharma Corporation**: A company developing innovative drug delivery technologies using cannabinoids for chronic pain treatment. - **Wavegate Corporation**: Developing the Ellipse Spinal Cord Stimulator Platform for chronic pain treatment utilizing optical reflectometry technology. ### Partnerships and Collaborations - **SAFE Project and Alternative Pain Treatment Directory**: Collaborating to promote non-addictive pain management solutions and reduce opioid dependence through education and advocacy. - **NorCal Pain and PatchRx**: Implementing innovative medication management technology to enhance patient-centered pain management. - **ACP and AAFP**: Collaborated to develop clinical guidelines for acute pain management, focusing on both pharmacologic and nonpharmacologic treatments. - **Vertex Pharmaceuticals and various research institutions**: Collaboration to develop and test new non-opioid pain treatments. - **Aclarion**: Expanding partnerships in the U.S. personal injury and worker compensation sectors to improve pain diagnosis and treatment outcomes. - **CHOICE Institute & Truveta**: Partnering to utilize electronic health record data for research in various therapeutic areas, including pain management. - **University of Arkansas and NIH**: Collaboration to investigate healthcare provider biases against minority patients in pain management. - **Innocan Pharma**: Engaged Dr. William K. Schmidt to assist with FDA submission processes for chronic pain treatment. - **Clearway Pain Solutions and Eastern Neurodiagnostic Associates**: This acquisition aims to enhance pain management and neurological care capabilities in Southern New Jersey. - **SciSparc and Polyrizon**: Entered an exclusive patent license agreement for the SCI-160 program, focusing on pain treatment. - **Octavian Therapeutics and Waterseid Partners Inc.**: Octavian has engaged Waterseid for investor relations to support its drug development efforts in neuropathic pain and oncology. - **Medasense and Nihon Kohden**: Formed a strategic partnership for the exclusive distribution of Medasense's pain monitoring device in Japan. - **NIH HEAL Initiative**: Brixton Biosciences received a $2 million grant to support the development of Neural Ice, aligning with the initiative's goal to combat the opioid crisis. - **Carilion Clinic and TytoCare**: Enhancing telehealth capabilities for remote diagnosis and treatment through virtual physical examinations. - **Hinge Health and Midi Health**: Partnering to provide clinical care alongside movement-based menopause support. - **Queensland Brain Institute & Abbott Neuromodulation**: Collaborated to develop a remote care platform for monitoring and treating neurological disorders. - **SiteOne Therapeutics and Vertex Pharmaceuticals**: Collaboration to explore the inhibition of NaV1.7 sodium channels as part of SiteOne's therapeutic strategy. - **RAPT Therapeutics and Shanghai Jemincare Pharmaceutical**: Exclusive agreement for the development and commercialization of RPT904, an anti-IgE monoclonal antibody. - **VoiceCare AI and Mayo Clinic**: Partnering to pilot intelligent voice automation technology for patient pre-authorization and benefit confirmations. ### Innovations, Trends, and Initiatives - **Non-Opioid Pain Management**: Growing focus on non-opioid pain treatments, with companies like SiteOne and Channel Therapeutics developing sodium channel inhibitors. - **Non-Pharmacological Approaches**: Growing interest in non-drug pain management techniques, such as nutrition and movement therapies, as effective alternatives to traditional pharmacological treatments. - **AI-guided Sensors**: Advancements in AI-based analgesia devices and wearable sensors for real-time pain assessment and personalized treatment. - **CA8* Therapeutic Technology**: Adolore's innovative approach to non-opioid pain management using gene therapies. - **Neurostimulation Therapy**: Utilizes electrical impulses to block pain signals, with advancements leading to smaller, smartphone-controlled devices. - **Cryoneurolysis**: A technique gaining popularity for long-lasting pain relief by numbing specific nerves using extreme cold. - **Neural Ice**: Brixton's injectable solution aims to provide drug-free pain management for chronic and post-operative pain, expanding clinical applications. - **Nociscan Platform**: Utilizes augmented intelligence algorithms and biomarkers to revolutionize chronic pain treatment. - **Virtual Reality in Pain Management**: VR technologies are being utilized for therapeutic interventions to alleviate pain and anxiety in clinical settings. - **Platelet-Rich Plasma (PRP) Treatments**: Connecticut Pain Solutions is offering advanced PRP treatments to accelerate healing and improve quality of life for patients. - **AI-driven Applications**: Revolutionizing chronic pain management by using machine learning to track pain levels and suggest personalized treatments. - **Centre for Innovation in Pain and Health Research**: Launched by the University of Queensland to enhance outcomes for individuals suffering from pain through collaborative research. - **AI-Powered Pain Monitoring**: Medasense's NOL device utilizes AI for real-time pain assessment, aiming to enhance pain management practices. - **Suzetrigine Approval**: The FDA has approved this new non-opioid pain treatment, marking a significant development in acute pain management. - **Elenagen**: CureLab's innovative therapy targets chronic inflammation to manage chronic pain, with promising preclinical results. - **Phosphatidic Acid Research**: Rutgers researchers identified phosphatidic acid as a potential therapeutic target for reducing pain sensitivity. - **Suzetrigine**: Vertex Pharmaceuticals is advancing suzetrigine as a non-opioid treatment for acute pain, aiming to fill the treatment gap between opioids and existing therapies. - **Machine Learning in Pain Research**: Washington University is utilizing machine learning to classify patient subgroups based on genetic, molecular, and behavioral patterns related to chronic pain. - **Nociception Level Index (NOL)**: Medasense's AI-powered monitoring system for objective pain assessment. - **Suzetrigine Development**: Vertex Pharmaceuticals is nearing FDA approval for suzetrigine, a non-opioid treatment for acute pain, marking a significant advancement in pain management. ### Challenges and Concerns - **Healthcare Access**: Efforts to improve healthcare equity and access to pain management treatments are ongoing, with a focus on addressing disparities. - **Chronic Pain Management**: The medical community struggles with adequately addressing chronic pain, leading to patient frustration and a demand for alternative therapies. - **Access to Non-Medication Treatments**: Barriers to implementing non-medication pain treatments, such as mindfulness interventions, in healthcare systems need to be addressed. - **Market Growth and Competition**: The pain treatment market is projected to grow significantly, leading to increased competition among companies developing new pain management solutions. - **Bias in Pain Treatment**: Women suffering from chronic pain face significant disparities in treatment, often receiving inadequate care due to systemic biases. - **Stigma in Pain Management**: Patients with conditions like sickle cell disease often face stigma when seeking pain medication, complicating their treatment. - **Opioid Crisis**: The ongoing opioid crisis has prompted healthcare providers to seek alternatives for pain management, highlighting the need for innovative non-opioid treatments. - **Implicit Bias in Pain Management**: Disparities in pain treatment for patients of color due to biases among healthcare providers. - **Patient Distress**: Issues of stigma and lack of control in pain management for patients with chronic conditions like sickle cell disease. - **Healthcare Provider Bias**: Research indicates that biases among healthcare providers can affect pain treatment outcomes for minority patients, highlighting the need for improved training and awareness. - **Technical and Ethical Challenges**: Concerns regarding the integration of AI technologies in pain management and the need for effective implementation. - **NIH Funding Cuts**: Recent cuts to NIH funding for indirect costs could impact research efforts in pain treatment and management. - **Regulatory Environment**: Physicians face challenges in prescribing pain medications due to legal scrutiny, impacting their willingness to treat patients effectively. - **Drug Shortages**: Significant drug shortages in the U.S. affect critical pain management medications, prompting regulatory responses. ## Related Topics [[Pain Management]]; [[Pain Medicine]]